ribociclib
novartis
['kisqali', 'breast', 'novartis', '$nvs']
at asco, novartis presents data showing kisqali cut relapse rates by 25% in early breast cancer. results are from a phase iii trial, which was stopped early after hitting its primary endpoint of invasive disease-free survival. $nvs #asco23 #breastcancer 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt